Recent

% | $
Quotes you view appear here for quick access.

ImmunoGen, Inc. Message Board

  • bioimmunomabman bioimmunomabman Apr 25, 2014 9:33 AM Flag

    Headlines worse than reality

    It's a good day to cover shorts, or buy, the quarter looked worse due to a 1-time charge. They should have reported an adjusted number. Revs were disappointing, progress is disappointing, but at this price, IMGN is a value biotech thanks to DJ's poor leadership. Not happy with the miss, but not panicking..

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Hey yer fuzzy (I prefer fuzzy instead of furry) friend here. I say the piggy might be a pretty good buy around $11 maybe $10. The dog barks. The shorties be gettin' a little oinker here too so they better be coverin' or the dog is gonna bite. Yas might start buyin' sooner if yer gonna be slummin' around this dumper fer a long time. The dog says OK if yas be longers and don't be SQUEEEEEEEEEALIN'.

    • I think the dip in price reflects what you're saying: it's not as bad as they make it out to be. Many biotechs are in the red and some have lost almost as much as imgn without a quarterly miss.

    • I think a miss or hit of 6 million is inconsequential. I posted yesterday that the abstracts at asco are not that great, but what I'm holding out here for is BT-062 in july-september. I think when we get the buy in then (speculating on the date) that will lift the stock significantly. As long as they have hunkered down now and are not bleeding too much cash, they will make it. They have so many partnered drugs, it seems like one will EVENTUALLY be a hit, it's just a shame they can't push faster, only the partner can. I'm grabbing some October contracts now. It can't get worse now unless another drug drops from the pipeline.

 
IMGN
7.02-0.11(-1.54%)Feb 10 4:00 PMEST